Doctor of Osteopathy Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Amanda McConnell-Mack

Neurology Gallipolis, OH Doctor of Osteopathy

NPI 1740424076 CMS profile 498770

90 Jackson Pike, Gallipolis, OH 45631

Open in the dashboard

General payments

$8,747

505 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$2,193 paid to institutions, not to them · program year 2019

Through program year 2025, Amanda McConnell-Mack of Gallipolis, OH is reported in the CMS Open Payments database as having received $8,747 across 505 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $2,193 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 73rd percentile of Neurology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,580 84
2024 General $1,700 90
2023 General $1,458 80
2022 General $1,064 56
2021 General $656 42
2020 General $617 39
2019 General $1,672 114

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Amanda McConnell-Mack
  • Neurology median
  • Middle half of Neurology
  • National median

In program year 2025, general payments to Amanda McConnell-Mack were reported at $1,580. Among 11,022 Neurology profiles paid that year, the median was $457 and the middle half received between $118 and $2,344.

Show as a table
Year Amanda McConnell-Mack Neurology median Middle half National median
2019 $1,672 $474 $118–$2,177 $163
2020 $617 $367 $82–$2,309 $114
2021 $656 $438 $104–$2,547 $132
2022 $1,064 $442 $103–$2,388 $149
2023 $1,458 $464 $119–$2,312 $160
2024 $1,700 $468 $119–$2,323 $164
2025 $1,580 $457 $118–$2,344 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AbbVie, Inc. $985 70 payments
  2. Biogen, Inc. $805 52 payments
  3. Jazz Pharmaceuticals Inc. $603 22 payments
  4. UCB, Inc. $455 26 payments
  5. Allergan Inc. $442 33 payments
  6. SK Life Science, Inc. $425 21 payments
  7. US WorldMeds, LLC $394 15 payments
  8. Lilly USA, LLC $360 22 payments
  9. Amgen Inc. $322 18 payments
  10. Novartis Pharmaceuticals Corporation $282 18 payments
  11. Other $3,673 208 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $8,275 493 payments
  2. Education $367 7 payments
  3. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $105 5 payments
Products named General payments · program years 2019–2025
  1. UBRELVY $576 42 payments
  2. QULIPTA $517 36 payments
  3. TYSABRI $488 33 payments
  4. BOTOX $422 30 payments
  5. VUMERITY Neurology $407 27 payments
  6. AIMOVIG $373 23 payments
  7. XYWAV $328 12 payments
  8. Briviact $303 20 payments
  9. VUMERITY Neurology $260 15 payments
  10. EMGALITY $249 15 payments
  11. Other $5,568 309 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 91 drugs

Part D claims

5,531

Median for Neurology: 833

Drug cost

$1,341,055

Median for Neurology: $202,670

Branded share of claims

23.9%

Median for Neurology: 25.9%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Privigen Immun Glob G(Igg)/Pro/Iga 0-50 Brand 32 $272,868
Xywav Sodium,calcium,mag,pot Oxybate Brand 11 $187,333
Nuplazid Pimavanserin Tartrate Brand 25 $124,865
Austedo Deutetrabenazine Brand 13 $78,490
Xcopri Cenobamate Brand 44 $60,948
Nurtec Odt Rimegepant Sulfate Brand 28 $44,532
Valtoco Diazepam Brand 31 $43,947
Qulipta Atogepant Brand 35 $42,881
Vimpat Lacosamide Brand 17 $38,919
Rexulti Brexpiprazole Brand 22 $37,327

The 10 drugs with the highest cost, of 91 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 13,695 Part D prescribers listed as Neurology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 36 billing codes

Paid by Medicare

$84,858

Medicare's payments for the services billed

Medicare patients

550

Average age 70

Services billed

5,007

318 women, 232 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 61%
Depression 38%
Diabetes 37%
Ischemic heart disease 28%
Chronic kidney disease 27%
Heart failure 19%
COPD 19%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 26 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
Gocovri
  • US WorldMeds, LLC $215
$215 — —
QULIPTA
  • AbbVie, Inc. $113
$113 35 —
UBRELVY
  • AbbVie, Inc. $112
$112 11 —
EMGALITY
  • Lilly USA, LLC $104
$104 37 —
VUMERITY
  • Biogen, Inc. $98
$98 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 26 with Patron

Records

505 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Neurology in Ohio

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record